


Public Reporting of Outcomes for Breast CP3R (Cancer Program Practice Profile Report)

Baylor Scott & White Medical Center - Round Rock is committed to providing quality cancer care to our patients. To this end, our facility is currently in the process of becoming an accredited cancer program through the American College of Surgeons Commission on Cancer. There are roughly 1,500 such accredited cancer programs across the country and Puerto Rico. By working toward an accredited cancer program, Baylor Scott & White provides a multidisciplinary, team approach to coordinate quality cancer treatment options while offering comprehensive services and equipment. Accreditation demonstrates our cancer program’s commitment to provide care from prevention through survivorship, with a focus on quality of life. The goal of Baylor Scott & White Medical Center - Round Rock is to become accredited by the summer of 2017.

The Baylor Scott & White Medical Center - Round Rock Cancer Committee has chosen to publicly report 2015 outcomes for the Breast CP3R (Cancer Program Practice Profile Report) measures to fulfill this requirement of accreditation.*


Radiation Therapy Administered Following Breast Conserving Surgery (BCSRT)



Radiation therapy is administered within one year (365 days of diagnosis) for women under age 70 receiving breast-conserving surgery for breast cancer. In 2015, 22 of our patients met the criteria for this measure, and 100 percent of those patients received the expected treatment, exceeding the expected benchmark of 90 percent.


Combination Chemotherapy Recommended/Administered for Hormone Receptor Negative Breast Cancer (MAC)

Combination chemotherapy is recommended or administered within four months (120 days) of diagnosis for women under 70 with AJCC T1cN0M0, or Stage IB-III hormone receptor negative breast cancer. In 2015, four of our patients met the criteria for this measure, and 100 percent of those patients received the expected treatment, exceeding expected benchmark of 90 percent.



*Standard 1.12


Breast Conserving Surgery (BCS)




Breast conservation surgery rate for women with AJCC clinical stage 0, I, or II breast cancer. In 2015, 78.3 percent of our patients had breast conservation surgery. There is currently no benchmark for this measure.

Hormone Therapy Recommended/Administered for Hormone Receptor Positive Breast Cancer (HT)

Hormone therapy or third-generation aromatase inhibitor is recommended or administered within one year (365 days) of diagnosis for women under 70 with AJCC T1cN0M0, or Stage IB-III hormone receptor positive breast cancer. In 2015, 29 of our patients met the criteria for this measure, and 100 percent of those patients received the expected treatment, exceeding expected benchmark of 90 percent.



Radiation Therapy Recommended/Administered Following Mastectomy (MASTRT)



Radiation therapy is recommended or administered following any mastectomy within one year (365 days) of diagnosis of breast cancer for women with ≥ 4 positive regional lymph nodes. In 2015, one of our patients met the criteria for this measure, and that patient received the expected treatment (100 percent), exceeding expected benchmark of 90 percent.

Needle Biopsy to Establish Diagnosis of Breast Cancer (nBx)

Image or palpation-guided needle biopsy to the primary site is performed to establish diagnosis of breast cancer. In 2015, 71 of our patients met the criteria for this measure, and 98.5 percent of those patients received the expected treatment, exceeding expected benchmark of 80 percent.

